Scientific Publications

News

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 is a CD7-targeting, allogeneic, fratricide-resistant […]

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

American Society of Hematology Annual Meeting, Ghobadi et al, December 2023

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Science Translational Medicine, Berrien-Elliot et al, February 2022

Memory-like differentiation enhances NK cell responses to melanoma

Clin Cancer Res, Marin et al, June 2021

Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Cancer Discovery, Berrien-Elliott et al, December 2020

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, Gang et al, November 2020

Memory-like natural killer cells for cancer immunotherapy

Seminars in Hematology, Gang et al, November 2020

Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies

Best Practice & Research Clinical Haematology, Cooper and DiPersio, December 2019

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Leukemia, Cooper et al, February 2018

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses

Biol Blood Marrow Transplant, Wagner et al, March 2017

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Science Translational Medicine, Romee et al, September 2016

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Biol Blood Marrow Transplant, Leong et al, April 2014

Cytokine activation induces human memory-like NK cells.

Blood, Romee et al, December 2012

Latest News

Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers

Additional capital brings total raised to $150 million in a Series C financing Funds support …

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a significant unmet medical need. WU-CART-007 …

Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness …